T-cell depleted allogeneic hematopoietic cell transplants as a platform for adoptive therapy with leukemia selective or virus-specific T-cells.

about

T-Cell Manipulation Strategies to Prevent Graft-Versus-Host Disease in Haploidentical Stem Cell Transplantation.

P2860

Q55060181-6734E15A-9CE8-4F21-8433-9A3C90859D9B

P2860

T-cell depleted allogeneic hematopoietic cell transplants as a platform for adoptive therapy with leukemia selective or virus-specific T-cells.

Item

http://www.wikidata.org/entity/Q38514497

description

2015 nî lūn-bûn

@nan

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

2015年论文

@zh

2015年论文

@zh-cn

name

T-cell depleted allogeneic hem ...... ive or virus-specific T-cells.

@en

type

Item

label

T-cell depleted allogeneic hem ...... ive or virus-specific T-cells.

@en

prefLabel

T-cell depleted allogeneic hem ...... ive or virus-specific T-cells.

@en

P1476

T-cell depleted allogeneic hem ...... ive or virus-specific T-cells.

@en

P2093

A N Hasan

http://www.w3.org/2001/XMLSchema#string

E Doubrovina

http://www.w3.org/2001/XMLSchema#string

G Koehne

http://www.w3.org/2001/XMLSchema#string

R J O'Reilly

http://www.w3.org/2001/XMLSchema#string

S Prockop

http://www.w3.org/2001/XMLSchema#string

P2860

Ex vivo T cell-depleted versus unmodified allografts in patients with acute myeloid leukemia in first complete remission.

High-dose cyclophosphamide as single-agent, short-course prophylaxis of graft-versus-host disease.

Transplantation outcomes for severe combined immunodeficiency, 2000-2009.

Outcomes of pediatric bone marrow transplantation for leukemia and myelodysplasia using matched sibling, mismatched related, or matched unrelated donors.

Effect of graft-versus-host disease prophylaxis on 3-year disease-free survival in recipients of unrelated donor bone marrow (T-cell Depletion Trial): a multi-centre, randomised phase II-III trial.

Successful treatment of EBV-associated posttransplantation lymphoma after cord blood transplantation using third-party EBV-specific cytotoxic T lymphocytes.

Allogeneic compared with autologous stem cell transplantation in the treatment of patients younger than 46 years with acute myeloid leukemia (AML) in first complete remission (CR1): an intention-to-treat analysis of the EORTC/GIMEMAAML-10 trial.

Allogeneic cytotoxic T-cell therapy for EBV-positive posttransplantation lymphoproliferative disease: results of a phase 2 multicenter clinical trial.

T cell-depleted unrelated donor stem cell transplantation provides favorable disease-free survival for adults with hematologic malignancies

Low risk of chronic graft-versus-host disease and relapse associated with T cell-depleted peripheral blood stem cell transplantation for acute myelogenous leukemia in first remission: results of the blood and marrow transplant clinical trials networ

P2888

bmt.2015.95

P304

S43-50

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/BMT.2015.95

http://www.w3.org/2001/XMLSchema#string

P407

English

P478

50 Suppl 2

http://www.w3.org/2001/XMLSchema#string

P577

2015-06-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P6179

1008404210

http://www.w3.org/2001/XMLSchema#string

P698

26039207

http://www.w3.org/2001/XMLSchema#string

P932

4787269

http://www.w3.org/2001/XMLSchema#string

T-cell depleted allogeneic hematopoietic cell transplants as a platform for adoptive therapy with leukemia selective or virus-specific T-cells.

about

P2860

P2860

T-cell depleted allogeneic hematopoietic cell transplants as a platform for adoptive therapy with leukemia selective or virus-specific T-cells.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P407

P478

P577

P6179

P698

P932

P356

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P407

P478

P577

P6179

P698

P932